Biotech Firm HuaJian Future Files for Hong Kong IPO; Guangzhou Pharma Group to Take Control of DAAN Gene to Expand IVD Portfolio

Biotech's IPO in Hong Kong

On May 11, the Hong Kong Stock Exchange's Disclosure Easy website officially posted the prospectus of HJ Science. This clinical-stage biotechnology company, rooted in Chengdu, has formally launched its bid for the main board of the Hong Kong stock market, with CITIC Securities as the exclusive sponsor. Founded by Ji Jianxin, a prominent figure bridging the fields of pharmaceutical science and industry, HJ Science has rapidly completed team building, technology platform implementation, pipeline clinical advancement, and multiple rounds of capital financing in recent years. Following the C2 round of financing before its IPO, the company’s post-money valuation has reached 2.7 billion yuan. (Source: Arterial Network)

Guangzhou Pharmaceutical Group to Control DaAn Gene and Layout in the In Vitro Diagnostics Field

On May 16, DaAn Gene announced that Guangzhou Pharmaceutical Group's GPCapital had signed a controlling equity acquisition agreement with multiple parties to indirectly control 26.63% of DaAn Gene’s shares, becoming its indirect controlling shareholder. This transaction falls under the professional integration within the Guangzhou state-owned assets system, with the actual controller being the Guangzhou Municipal People's Government. DaAn Gene is one of the in vitro diagnostic enterprises with advanced technology and comprehensive products. GPCapital is the core capital platform for Guangzhou Pharmaceutical Group's strategic development. This acquisition adds another listed company to Guangzhou Pharmaceutical Group, enhancing its industrial layout and creating a new engine for its "15th Five-Year Plan" strategic goals. The number of listed companies under its holding and strategic investment has increased to four. (Source: Sina Finance)

Pharmacin Advances into Innovative Drugs

On May 13, Shenzhen Pharmacin Co., Ltd. ("Pharmacin") and Hefei OpenSRCBio Pharmaceutical Technology Co., Ltd. ("OpenSRCBio") announced that they had signed a cooperation agreement. According to the agreement, the two parties will collaborate on OpenSRCBio's self-developed PDE4B inhibitor project, with idiopathic pulmonary fibrosis (Idiopathic Pulmonary Fibrosis, IPF) as the first targeted indication. Pharmacin will lead preclinical research, drugability studies, complex formulation development, CMC pathway design, and further advance IND/CTA submissions and subsequent clinical development. (Source: Sina Finance)

Boling Capital Completes Strategic Investment in Xianweide Biotech

Recently, Bo Ling Capital officially completed the strategic investment in Beijing Xian Wei De Biotechnology Center (Limited Partnership) (hereinafter referred to as "Xian Wei De Biotech"). Xian Wei De Biotech is the core shareholder of Aeonvital. Aeonvital is an innovative biopharmaceutical company focusing on cell and gene therapy, specializing in the development of innovative Tumor-Infiltrating Lymphocyte (TIL) therapies and nucleic acid drugs (DNA and mRNA). It is a national industry standard-setter for TIL cell therapy and a leading enterprise in HPV therapeutic vaccines. (Source: Sina Finance)

Brainsmart Technology Completes Over Ten Million USD Angel Round Financing

Recently, Brainsmart Technology (hereinafter referred to as "Brainsmart Technology" or "the Company"), an innovative brain-computer interface company, announced that it has completed an angel round series financing of over ten million US dollars, led successively by Kangjun Capital and BlueRun Ventures, with Fosun Health Capital participating. The proceeds from this round of financing will be mainly used to advance product engineering, the development of neural foundation models, and the construction of GMP production facilities, accelerating the resolution of challenges related to the stable use of brain-computer interfaces in real-world scenarios. (Source: Arterial Network)

Xinguang Bio Completes Millions of Yuan in Angel Round Financing

Central Biotech (Changsha) Co., Ltd. announced the completion of millions of yuan in angel round funding exclusively invested by Hunan Province College Student Entrepreneurship Investment Fund. The funds from this round will mainly be used for the research and development iteration of the subsidiary company Xinguang Bio's black light optoelectronic tweezer device, team expansion, and market promotion, aiming to break the long-term monopoly of high-end scientific instruments by foreign brands and achieve independent control of core life science tools. (Source: Arterial Network)

Raythink Union Secures Nearly RMB 100 Million in Pre-A Round Financing

Recently, Brainsmart Technology completed a nearly 100-million-yuan Pre-A round of financing. This round was led by NuoYu Capital and Well Lead Medical, with participation from Chuchang Fund and Oak Investment, while existing shareholders StarVest Investment and Suzhou Venture Capital-Angel Mother Fund continued to increase their investment. Wasp Capital served as the exclusive financial advisor for this round. The funds will primarily be used to advance the implementation of the company’s full-stack technology for implantable bidirectional brain-computer interfaces; accelerate the mass production and clinical progress of "brain-spine interface" application scenarios; comprehensively explore various application scenarios based on the company’s brain-computer interface technology platform; and continuously empower the commercialization of the company’s certified and marketed products. (Source: Arterial Network)

Immunocan Completes 250 Million Yuan Series A Financing

Shanghai Imunocare Biotechnology Co., Ltd. (hereinafter referred to as "Imunocare") announced the completion of a 250 million yuan Series A round of financing. This round of financing was led by Vivo Capital, with Gaomai Yuanhang following the investment. Existing shareholders Xicheng Jinrui and Taiyu Investment significantly exceeded their additional investments. The funds from this round will mainly be used to accelerate the ongoing research and development of the gene-edited animal platform, the commercial implementation of the fully human antibody rabbit platform, the establishment of an AI antibody drug screening platform, the development of scaffold antibodies for complex targets, as well as for the company's daily operations and team expansion. (Source: Arterial Network)

Jilin Province Medical Insurance Bureau Releases "Announcement on the First Batch of Termination or Suspension of Provincial Direct定点 Medical Insurance Service Agreements in 2026"

Jilin Province Medical Insurance Bureau Releases "Announcement on the First Batch of Termination or Suspension of Provincial Direct定点 Medical Insurance Service Agreements in 2026" (hereinafter referred to as the "Announcement"), publicly announcing the list of medical institutions whose medical insurance service agreements have been terminated or suspended. The Announcement shows that: As of April 20, 2026, the first batch includes 88 medical institutions whose medical insurance service agreements were terminated or suspended, including 65 agreements terminated and 23 agreements suspended. Among the 65 medical institutions whose agreements were terminated, 14 were terminated due to violations of the medical insurance agreement, including 13 pharmacies; 51 voluntarily applied for termination, including 50 pharmacies. (Source: Menet)